Clinical trials

Current Open Bladder Cancer Trials

 

Suspected Bladder Cancer

UROX BIOMARKER

This trial will need a urine sample from participants who are under investigation for possible bladder cancer and are due to undergo a standard-of-care investigative cystoscopy and biopsy. This study tests whether the UroX biomarker can be detected in urine samples and therefore be a way of diagnosing patients. Both healthy volunteers and bladder cancer participants are needed. 

East and North Hertfordshire NHS Trust

ClinicalTrials.gov ID: NCT03973307

 

Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.

The aim of the study is to assess the feasibility of genomic and epigenetic analysis of rectal mucus to detect non-colorectal cancers of the aero- digestive tract using samples collected by the OriCol™ Sampling Device. The primary objective of the study is to assess whether significant changes in DNA mutation and methylation associated with Non-colorectal cancers of the Aerodigestive Tract (NCRCADT) can be detected in rectal mucus as shed cells and cell-free DNA (cfDNA) pass through the gut and theoretically can be collected from rectal mucus. Secondary objectives will assess the participant acceptability of the OriCol™ Sampling Device for Upper GI and Lung Pathology as well as contributing to a genomic library collating information about rectal mucus

Royal Devon & Exeter NHS Foundation Trust, Exeter

ClinicalTrials.gov ID:  NCT05102110

 

Urinary tract squamous cell carcinoma (UTSCC)

AURORA

This trial is for people with urinary tract squamous cell carcinoma (UTSCC). People participating in this trial will receive an immunotherapy called atezolizumab. This study is investigating whether atezolizumab is tolerable, safe and will help prolong the life of people with urinary tract squamous cell carcinoma.

Locations: University Hospital Southampton, University College London Hospital, James Cook Hospital Middlesborough, Western General Hospital Edinburgh, Beatson West of Scotland Cancer Centre Glasgow, Royal Preston Hospital, Nottingham, Velindre (Cardiff), The Christie Hospital Manchester, Clatterbridge Hospital Liverpool, Royal Marsden Hospital

ClinicalTrials.gov ID: NCT05038657

 

Non-Muscle-Invasive Bladder Cancer (NMIBC)

KEYNOTE-676

This study is for people with high-risk non-muscle-invasive bladder cancer that is persistent or recurrent following BCG induction. Patients will receive a drug called pembrolizumab along with BCG or BCG without pembrolizumab. This study looks at how well pembrolizumab works with BCG in people with bladder cancer.

Raigmore Hospital Inverness,  St. Bartholomew's Hospital London,  St Georges University Hospitals NHS Foundation Trust London

ClinicalTrials.gov ID: NCT03711032

 

DURANCE

This study is for people with non-muscle invasive bladder cancer that is considered to be at high-risk of spreading into the muscles that line the bladder, and the standard treatments are either not suitable or are not working. The study is looking to see if giving two treatments – an immunotherapy drug (durvalumab) together with a vaccine (S-488210/S-488211) – is a safe and effective treatment option for non-muscle invasive bladder cancer. 

The Royal Marsden NHS Foundation Trust London,  University College London Hospital NHS Foundation Trust,  University Hospital Southampton NHS Foundation Trust

ClinicalTrials.gov ID: NCT04106115

 

CR108699

This study aims to evaluate recurrence-free survival in people treated with erdafitinib compared to their doctor's choice for people with high-risk non-muscle-invasive bladder cancer who harbour FGFR mutations or fusions and who recurred after BCG therapy.

Christie Hospital Manchester,  University of Sheffield Teaching Hospitals,  Lister Hospital Stevenage

ClinicalTrials.gov ID: NCT04172675

 

SUNRISE-1

This study is for people with high-risk Non-Muscle Invasive Bladder Cancer. TAR-200 is inserted into the bladder - it is an investigational product that is comprised of a drug (Cetrelimab) and a medical device. This study consists of 3 periods: screening phase (up to 42 days); treatment phase (up to 2 years); follow-up phase (up to 5 years). The total duration of study is up to 6 years and 7 months.

NHS Greater Glasgow and Clyde

ClinicalTrials.gov Identifier: NCT04640623

 

RESECT: Improving Quality in TURBT Surgery.

The most important step in the diagnosis and treatment of Non-Muscle Invasive Bladder Cancer is the first surgical procedure called the transurethral resection of bladder tumour (TURBT). There is evidence that the quality of the TURBT operation, and the use of a single administration of bladder chemotherapy following the operation, can reduce cancer recurrence rates and progression to more invasive cancer. There is anecdotal evidence that the quality of TURBT surgery and the usage of intravesical chemotherapy varies widely between hospitals and thus may result in worse outcomes for some patients.

The primary objective of the study is to determine if audit and feedback can improve the quality of TURBT surgery and if this reduces the recurrence of Non-Muscle Invasive Bladder Cancer

BURST, London

ClinicalTrials.gov ID: NCT05154084

 

 

Muscle-invasive, advanced or metastatic bladder cancer

DISCUS

This study is for people with locally advanced or metastatic urothelial cancer. It is a randomised phase II study comparing 3 vs 6 cycles of platinum-based chemotherapy before maintenance avelumab immunotherapy.

Queen Mary University of London, Western General Hospital Edinburgh

Clinicaltrialsregister.eu: 2021-001975-17

 

RE-ARM

This study is for people with cancer of the urinary system that has spread to other places in the body (advanced urothelial cancer). Patients will be receiving a drug called atezolizumab. Upon entering the study, patients will continue to receive atezolizumab and may also receive five doses of radiotherapy. This study investigates whether radiotherapy can improve response to atezolizumab for people treated for advanced urothelial cancer.

London, Manchester, Sutton, Truro

International Trial Number: ISRCTN12606219

 

PLUMMB

This study is for people with muscle-invasive or advanced bladder cancer. It aims to determine the safety and effectiveness of immunotherapy with radiotherapy. It is a phase 1 clinical trial and will start with pembrolizumab before beginning a radiotherapy course.

Royal Marsden NHS Foundation Trust

ClinicalTrials.gov ID: NCT02560636

 

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

The primary purpose of this study is to identify the recommended Phase 2 dose [RP2D(s)] for JNJ-63723283 in Part 1, to assess the anti-tumour activity of JNJ-63723283 at the RP2D(s) in participants with selected advanced cancers including non-small-cell lung cancer (NSCLC), melanoma, renal, bladder, small-cell lung cancer (SCLC), gastric/oesophagal cancer, and high-level microsatellite instability (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer (CRC) in Part 2, to determine one or more additional RP2Ds in Parts 3 and 4 and to evaluate JNJ-63723283 subcutaneous (SC) administration pharmacokinetics (PK) compared to JNJ-63723238 intravenous (IV) administration (Part 5).

Beatson West Of Scotland Cancer Centre,  Glasgow; Sarah Cannon Research Institute, London,  The Christie NHS Foundation Trust, Manchester,  Sir Bobby Robson Unit, Northern Centre for Cancer Care, Newcastle upon Tyne

ClinicalTrials.gov ID: NCT02908906

 

Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

This study is for people with muscle-invasive bladder cancer. This study looks at the use of the drug nivolumab with chemotherapy.

Chelmsford,  York,  Glasgow,  Lancaster,  London,  Oxford

ClinicalTrials.gov ID: NCT03661320

 

IGNYTE

This study looks at the drug RP1 alone and then RP1 with nivolumab. This trial needs participants with advanced and/or refractory solid tumours. This trial will determine the drug's maximum tolerated and recommended dose. It is for a range of cancers and includes bladder cancer. 

University of Leeds- Teaching Hospital,  Oxford University Hospitals NHS Trust,  Beatson West of Scotland Cancer Center Glasgow,  The Clatterbridge Cancer Centre NHS Foundation Trust Bebington,  Royal Marsden Hospital London,  Southampton General Hospital

ClinicalTrials.gov ID: NCT03767348

 

Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

This study is for people with advanced or metastatic bladder cancer previously treated with chemotherapy. Patients will receive a drug called atezolizumab. This study looks at how well this drug works in people with bladder cancer.

Barnet Hospital,  Royal United Hospital Bath,  Clatterbridge Cancer Centre Bebington,  Heartlands Hospital Birmingham,  Addenbrookes Hospital Cambridge,  Royal Surrey County Hospital Guildford,  Northwick Park Hospital Harrow,  Hull Royal Infirmary,  Airedale General Hospital Keighley,  Royal Marsden Hospital Kingston upon Thames,  St Bartholomew's Hospital London,  Royal Free Hospital London,  Guys and St Thomas Hospital London,  Queen Elizabeth Hospital London,  St George's Hospital London,  Royal Marsden Hospital, Fulham London,  Hammersmith Hospital London,  Charing Cross Hospital London,  Maidstone Hospital,  The Christie Manchester,  James Cook Hospital Middlesbrough,  Freeman Hospital Newcastle upon Tyne,  Nottingham City Hospital,  Churchill Hospital Oxford,  Weston Park Hospital Sheffield,  Royal Stoke University Hospital,  Royal Marsden Hospital Sutton,  Torbay Hospital,  Pinderfields General Hospital Wakefield,  Great Western Hospitals Wiltshire,  New Cross Hospital Wolverhampton,  York Hospital

ClinicalTrials.gov ID: NCT03782207 

 

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (STELLAR-001)

This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors.

Exelixis Clinical London,  Sutton,  Preston

ClinicalTrials.gov ID: NCT03845166

 

MORPHEUS-UC

This study is for advanced or metastatic bladder cancer patients who have progressed during or following chemotherapy. Patients will receive a drug called atezolizumab and perhaps one of the following drugs: enfortumab vedotin, niraparib, Hu5F9-G4, tiragolumab, sacituzumab govitecan, cisplatin, gemcitabine or tocilizumab.

Barts and The London,  Churchill Hospital Oxford,  Royal Marsden NHS Foundation Trust Sutton

ClinicalTrials.gov ID: NCT03869190

 

KEYNOTE-905/EV-303

This study is for people with muscle-invasive bladder cancer who are not eligible for cisplatin-based chemotherapy. Patients will receive either surgery alone, pembrolizumab plus surgery, or enfortumab vedotin plus pembrolizumab plus surgery. This study looks at how well pembrolizumab and enfortumab vedotin work together with surgery in people with bladder cancer.

Kent and Canterbury Hospital,  Lister Hospital, Barts Health NHS Trust,  The Royal Marsden Foundation Trust,  Imperial College Healthcare NHS Trust,  Western General Hospital Edinburgh,  Royal Cornwall Hospital

ClinicalTrials.gov ID: NCT03924895

 

A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With Ezabenlimab With or Without BI 754111

This study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumors). The second part is open to people with specific types of soft tissue sarcoma, advanced lung cancer, and cancer in the stomach, bladder or bile ducts.

The Royal Marsden Hospital, London

ClinicalTrials.gov ID:  NCT03964233

 

BAY2416964

In this study, researchers want to gather relevant information regarding the safety of BAY2416964 and how well the drug works in participants with a type of solid tumour that currently available drugs cannot cure. Researchers want to find the highest dose of BAY2416964 that participants could take without having too many side effects, how the drug is tolerated, and how the body absorbs, distributes and gets rid of the study drug.

Royal Marsden NHS Trust Surrey,  Beatson West of Scotland Cancer Centre Glasgow,  Christie Hospital Manchester

ClinicalTrials.gov ID: NCT04069026

 

MOMENTUM

This registry helps implement the MRI-guided Linear Accelerator radiation therapy system to improve patients' survival, local and regional tumour control and quality of life.

London, Manchester

ClinicalTrials.gov ID: NCT04075305

 

A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor of EZH2.

Leicester Royal Infirmary

ClinicalTrials.gov ID:  NCT04104776

 

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors. The main goals of this study are to:
1. Find the recommended dose of BT5528 that can be given safely to participants alone and in combination with nivolumab
2. Learn more about the side effects of BT5528
3. Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cancer (NSCLC), triple-negative breast cancer, head and neck cancer (HNSCC), and gastric/upper gastrointestinal cancer.
4. Learn more about BT5528 therapy alone and in combination with nivolumab

Cambridge University Hospitals NHS Foundation Trust,  St James's University Hospital, Leeds,  Sarah Cannon Research Institute UK, London,  The Christie NHS Foundation Trust, Manchester,  Sir Bobby Robson Cancer Trials Research Centre,  Newcastle Upon Tyne

ClinicalTrials.gov ID:  NCT04180371

 

KEYNOTE-992

This study is for people who have muscle-invasive bladder cancer. Patients will receive chemoradiotherapy and might also receive a drug called pembrolizumab. This study looks at how well pembrolizumab works with chemoradiotherapy in people with bladder cancer.

South Devon Healthcare Foundation Trust

ClinicalTrials.gov ID: NCT04241185

 

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

This trial will look at a drug called SEA-TGT to determine whether it is safe for patients with solid tumours and lymphomas. It will study SEA-TGT to find out what its side effects are. It will also study whether SEA-TGT works to treat solid tumours and lymphomas.

The Royal Marsden Hospital Surrey

ClinicalTrials.gov ID: NCT04254107

 

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety of INCB099318 in people with solid tumours. People in this study will be given INCB099318, an immunotherapy drug that is taken as a tablet. 

Western General Hospital Edinburgh,  St James University Hospital Leeds,  Guys and St Thomas NHS Foundation Trust London,  The Royal Marsden Hospital NHS Trust London,  Imperial College Healthcare NHS Trust Hammersmith Hospital London,  Freeman Hospital Newcastle Upon Tyne

ClinicalTrials.gov ID:  NCT04272034

 

A Study of SGN-B6A in Advanced Solid Tumors

This trial will look at a drug called SGN-B6A to determine whether it is safe for people with solid tumours. It will study SGN-B6A to find out what its side effects are. It will also study whether SGN-B6A works to treat solid tumours.

The Royal Marsden Hospital Surrey

ClinicalTrials.gov ID: NCT04389632

 

REFOCUS (RLY-4008-101)

This study is for people whose cancer cannot be removed with surgery or has spread to distant body parts. People must be positive for the FGFR2 biomarker to be eligible. Participants in the study will receive an investigational drug called RLY-4008. This Phase 1/2 clinical study is looking at the safety and clinical benefit (tumour shrinkage) of RLY-4008.

Sarah Cannon Research Institute London, University College London Hospitals NHS Foundation Trust, The Christie NHS Foundation Trust Manchester

ClinicalTrials.gov ID: NCT04526106

 

Study DRUG BT8009 in Subjects With Nectin-4 Expressing Advanced Solid Tumor Malignancies

Evaluating a drug called BT8009 alone and in combination with pembrolizumab in participants with advanced solid tumours associated with Nectin-4 expression or in participants with advanced solid tumour having kidney problems. The main goals of this study are to:
1. Find the recommended dose of BT8009 that can be given safely to participants alone and in combination with pembrolizumab
2. Learn more about the side effects and effectiveness of BT8009 alone and in combination with pembrolizumab
3. Learn more about BT8009 alone and in combination with pembrolizumab
4. Learn more about BT8009 alone in patients with renal insufficiency

Sarah Cannon Research Institute UK, London,  The Christie NHS Foundation Trust, Manchester

ClinicalTrials.gov ID:  NCT04561362

 

Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

This trial studies how well tucatinib works for solid tumours that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumours studied in this trial have either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). All participants will get both tucatinib and trastuzumab

The Royal Marsden Hospital, London,  Sarah Cannon Research Institute UK, London,  The Royal Marsden Hospital (Surrey), Sutton,   Guy's Hospital, London,

ClinicalTrials.gov ID:  NCT04579380

 

INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

This is a clinical study to investigate the safety, tolerability, PK profile, pharmacodynamics, and preliminary clinical efficacy of INCB106385 when given as monotherapy or in combination with INCMGA00012 in participants with selected CD8 T-cell-positive advanced solid tumours including SCCHN, NSCLC, ovarian cancer, CRPC, TNBC, bladder cancer, and specified GI malignancies (defined as CRC, gastric/GEJ cancer, HCC, PDAC, or SCAC)

Cambridge University Hospitals NHS Foundation Trust,  University of Glasgow, Glasgow,  Guys and St Thomas NHS Foundation Trust, London,  Imperial College Healthcare NHS Trust - Hammersmith Hospital, London,  The Christie NHS Foundation Trust Manchester,  Freeman Hospital Newcastle Upon Tyne Foundation NHS Trust

ClinicalTrials.gov ID:  NCT04580485

 

Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer (ABACUS-2)

See if the drug atezolizumab can reduce the size of tumours in patients with types of urothelial cancer before surgery. Atezolizumab is designed to stop a protein called PD-L1 (programmed death-ligand 1) being expressed on the cancer, allowing the immune system to recognise the tumour cells as foreign bodies and attack them. Atezolizumab has been shown to have activity in urothelial cancer which has spread.

Barts and London Hospital NHS Trust, London,

ClinicalTrials.gov ID:  NCT04624399

 

AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

Research Site, Cambridge,  Manchester,  Oxford,  Sutton

ClinicalTrials.gov Identifier:  NCT04644068

 

IMVIGOR011

This study is for people with high-risk muscle-invasive bladder cancer who have had a cystectomy. Patients will be followed up closely after their cystectomy and may receive the immunotherapy atezolizumab. This study is looking to see if atezolizumab can improve disease-free survival.

Belfast City Hospital,  Addenbrookes Hospital,  Western General Hospital Edinburgh,  St James Hospital,  Barts Hospital, University College London NHS Foundation Trust,  Derriford Hospital,  Royal Preston Hospital,  Weston Park Hospital,  Southampton University Hospitals NHS Trust,  Royal Marsden Hospital (Sutton).

ClinicalTrials.gov ID: NCT04660344

 

Magrolimab in Participants With Solid Tumors

Evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of magrolimab + docetaxel combination therapy in solid tumors (Safety Run-in Cohort 1, Phase 2 Cohorts 1a, 1b, and 1c) and to evaluate the efficacy of magrolimab + docetaxel combination therapy in solid tumors as determined by investigator-assessed objective response rate (ORR) (Phase 2 Cohorts 1a, 1b, and 1c)

Barts Health NHS Trust, London,  Guy's and St Thomas' NHS Foundation Trust, London

ClinicalTrials.gov ID:  NCT04827576

 

A Study of Disitamab Vedotin Alone and With Pembrolizumab in Urothelial Cancer That Expresses HER2

This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). It will also study what side effects happen when participants get the drug

Barts Health NHS Trust Saint Bartholomews Hospital, London

ClinicalTrials.gov ID:  NCT04879329

 

TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4)

The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with intravenous (IV) cetrelimab and IV cetrelimab alone.

Barts Health NHS Trust, London

ClinicalTrials.gov ID:  NCT04919512

 

VOLGA

A study to determine the efficacy and safety of durvalumab in combination with tremelimumab and enfortumab vedotin or durvalumab in combination with enfortumab vedotin in people ineligible for chemotherapy undergoing radical cystectomy for muscle-invasive bladder cancer

Research Sites: Glasgow Beatson West of Scotland Cancer Centre, London UCL NHS Foundation Trust, London Barts Cancer Institute.

ClinicalTrials.gov ID: NCT04960709

 

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

This open-label, First-into-Human (FIH) study will evaluate the safety, tolerability, pharmacokinetics (PK) and early efficacy of AVA6000, a FAP-activated pro-drug of doxorubicin, in patients with locally advanced and/or metastatic solid tumours. In Phase Ia, using a 3+3 design, escalating doses of AVA6000 will be administered to patients with a range of solid tumour types to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D). In Phase 1b, the selected RP2D dose will be assessed in one to three tumour types.

The Beatson West of Scotland Cancer Centre Glasgow,  St James's University Hospital Leeds,  The Royal Marsden, NHS Foundation Trust, London,  The Christie NHS Foundation Trust, Manchester,  The Freeman Hospital, Newcastle-upon-Tyne,  Weston Park Cancer Centre Sheffield

ClinicalTrials.gov Identifier: NCT04969835

 

EPRIMM

The investigators would like to test stool samples of patients with womb, cervix or bladder cancer having pelvic radiotherapy to see if there are differences in the type of gut bacteria between those who get severe bowel symptoms compared to those with mild bowel symptoms. They also want to see whether these differences in gut bacteria can tell who will develop severe bowel symptoms during or after radiotherapy and determine the effect of diet.

Manchester

ClinicalTrials.gov Identifier: NCT04995809

 

BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab

Researchers are looking for a better way to treat advanced solid cancers including head and neck cancer, lung cancer and bladder cancer. In some people with cancer a protein called Aryl Hydrocarbon Receptor (AhR) can prevent immune cells from fighting tumor cells. The study drug, BAY 2416964, is a small molecule which blocks the AhR allowing the body to use its immune response against the cancer cells. Researchers think that BAY 2416964 given together with a cancer treatment called pembrolizumab may help shrink tumors in people with cancer

Clatterbridge Centre for Oncology, Bebington, Merseyside,  Belfast City Hospital, Belfast,  Freeman Hospital, Newcastle Upon Tyne

ClinicalTrials.gov Identifier: NCT04999202

 

HMBD-001 in Advanced HER3 Positive Solid Tumours

This study evaluates HMBD-001 for treating people with bladder cancer who test positive for the HER3 biomarker. The main aims are to find out the maximum dose of HMBD-001 that can be given safely to patients alone and in combination with other anti-cancer agents, more about the potential side effects of HMBD-001 and how these can be treated.

Royal Marsden NHS Foundation Trust, London,  Churchill Hospital, Oxford

ClinicalTrials.gov Identifier: NCT05057013

 

Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.

Royal Marsden Hospital (Chelsea), London,  The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle,  Royal Cornwall Hospitals NHS Trust

ClinicalTrials.gov Identifier NCT05059522

 

IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with pembrolizumab, as First-line Treatment for Patients with Metastatic Urothelial Bladder Cancer (mUBC)

Guys and St Thomas Hospital, London

ClinicalTrials.gov Identifier NCT05077709

 

A Study of NX-1607 in Adults With Advanced Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies

Royal Marsden Hospital NHS Foundation Trust, Sutton,  University College London Hospitals NHS Foundation,  Addenbrookes Cambridge University Hospital, Cambridge,  Beatson West of Scotland Cancer Centre, Glasgow,  Sarah Cannon Research Institute, London,  The Christie NHS Foundation Trust, Manchester,  Churchill Hospital, Oxford

ClinicalTrials.gov ID: NCT05107674

 

Ex VIvo DEtermiNed Cancer Therapy (EVIDENT)

EVIDENT's aim is to test if ex vivo drug screening can predict whether patients with solid cancers will respond, or not respond, to standard care treatments. Patients undergoing standard care surgery to excise their tumour, those undergoing a biopsy, or those having a fluid aspirate of a solid tumour with surplus tissue available after diagnostic use will be eligible for this study. The specimen will then be assessed with ex vivo drug screening utilising all standard therapies and therapies that are more novel and in early stages of development. The results of the ex vivo drug screen will be compared to the cancer's actual response to standard care treatments for those that undergo therapy to determine how effective the test is at predicting treatment response.

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield

ClinicalTrials.gov ID:  NCT05231655

 

Understand the Most Important Factors for Patients When They Decide on the Type of Treatment They Receive for Muscle Invasive Bladder Cancer (MIBC).

Through our study, we aim to understand the most important factors for patients when they decide on the type of treatment they receive for MIBC. Our study consists of a discrete choice experiment (DCE): a type of questionnaire used to elicit preferences in the absence of data. DCEs are frequently used in oncological research to elicit preferences from participants without directly asking them to state their preferred options. Participants undertaking our DCE questionnaire will presented with a series of alternative hypothetical scenarios containing several variables or "attributes" (5), each of which may have a number of variations or "levels".

Guy's and St Thomas' NHS Foundation Trust, London

ClinicalTrials.gov ID: NCT05236218

 

OBSERVATIONAL STUDY OF AVELUMAB AS FIRST-LINE MAINTENANCE TREATMENT OF PATIENTS WITH ADVANCED UROTHELIAL CANCER AFTER CHEMOTHERAPY

A multi-centre non-interventional study to describe the early clinical experience of avelumab used as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are progression-free following platinum-based chemotherapy

University Hospitals Bristol, Bristol,  Beatson West of Scotland Cancer Centre, Glasgow,  Royal Surrey County Hospital, Guildford,  Guy's and St Thomas' Hospital, London,  The Christie NHS Foundation Trust, Manchester,  Churchill Hospital, Oxford,  Royal Preston Hospital, Preston,  Lister Hospital, Stevenage,  Clatterbridge Hospital, Wirral,

ClinicalTrials.gov ID: NCT05366725

 

Human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours

A Phase I/IIa First-in-human, Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants with Selected Advanced/Metastatic Solid Tumours

Research Sites: Cambridge,  Glasgow,  London,  Newcastle Upon Tyne

ClinicalTrials.gov ID: NCT05397171

 

Exploiting the Gut Microbiota and Its Metabolites in Pelvic Cancer

The gut bacteria can potentially influence responses to treatments in cancer by helping to change the responses to radiotherapy and chemotherapy. The interactions between these bacteria and the rest of our cells are only now becoming understood and there is little research on the interactions between these bacteria and cancer radiotherapy treatments in pelvic cancer

Aberdeen Royal Infirmary, Aberdeen

ClinicalTrials.gov ID: NCT05605353